Evidence map›Paper›PMID 26984535›Full record

ArticleActa neuropathologica communications2016

Chronic Toxoplasma gondii infection enhances β-amyloid phagocytosis and clearance by recruited monocytes.

Luisa Möhle, Nicole Israel, Kristin Paarmann, Markus Krohn, Sabine Pietkiewicz, Andreas Müller, Inna N Lavrik, Jeffrey S Buguliskis, Björn H Schott, Dirk Schlüter and 5 more

Open access · goldAbstract read
In one paragraph

Article in Acta neuropathologica communications, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed, 1 pooled it
5.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 1 synthesis or guideline pooled it, 110 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. iScience · 2026
    Article
  6. Article
  7. Beyond Latency: ChronicBiomedicines · 2025
    Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. mFrontiers in cell and developmental biology · 2024
    Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 2 countries.

Luisa MöhleInstitute for Medical Microbiology and Hospital Hygiene, University of Magdeburg, Leipziger Str. 44, 39120, Magdeburg, Germany.
Nicole IsraelInstitute for Molecular and Clinical Immunology, University of Magdeburg, Magdeburg, Germany.
Kristin PaarmannDepartment of Pathology (PAT), Translational Neurodegeneration Research and Neuropathology Lab, University of Oslo (UiO) and Oslo University Hospital (OUS), Oslo, Norway.
Markus KrohnDepartment of Pathology (PAT), Translational Neurodegeneration Research and Neuropathology Lab, University of Oslo (UiO) and Oslo University Hospital (OUS), Oslo, Norway.
Sabine PietkiewiczDepartment of Translational Inflammation Research, Institute of Experimental Internal Medicine, University of Magdeburg, Magdeburg, Germany.
Andreas MüllerInstitute for Molecular and Clinical Immunology, University of Magdeburg, Magdeburg, Germany.
Inna N LavrikDepartment of Translational Inflammation Research, Institute of Experimental Internal Medicine, University of Magdeburg, Magdeburg, Germany.
Jeffrey S BuguliskisGenetic Engineering and Biotechnology News, New York, USA.
Björn H SchottCenter for Behavioral Brain Sciences (CBBS), University of Magdeburg, Magdeburg, Germany.
Dirk SchlüterInstitute for Medical Microbiology and Hospital Hygiene, University of Magdeburg, Leipziger Str. 44, 39120, Magdeburg, Germany.
Eckart D GundelfingerCenter for Behavioral Brain Sciences (CBBS), University of Magdeburg, Magdeburg, Germany.
Dirk MontagNeurogenetics, Leibniz Institute for Neurobiology, Magdeburg, Germany.
Ulrike SeifertInstitute for Molecular and Clinical Immunology, University of Magdeburg, Magdeburg, Germany.
Jens PahnkeDepartment of Pathology (PAT), Translational Neurodegeneration Research and Neuropathology Lab, University of Oslo (UiO) and Oslo University Hospital (OUS), Oslo, Norway.
Ildiko Rita DunayInstitute for Medical Microbiology and Hospital Hygiene, University of Magdeburg, Leipziger Str. 44, 39120, Magdeburg, Germany. ildikodunay@gmail.com.ORCID http://orcid.org/0000-0002-9900-8605
University Hospital Magdeburg · DECenter for Behavioral Brain Sciences · DEOslo University Hospital · NOGerman Center for Neurodegenerative Diseases · DEHelmholtz Centre for Infection Research · DELeibniz Institute for Neurobiology · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAlzheimer's disease (AD) is associated with the accumulation of β-amyloid (Aβ) as senile plaques in the brain, thus leading to neurodegeneration and cognitive impairment. Plaque formation depends not merely on the amount of generated Aβ peptides, but more importantly on their effective removal. Chronic infections with neurotropic pathogens, most prominently the parasite Toxoplasma (T.) gondii, are frequent in the elderly, and it has been suggested that the resulting neuroinflammation may influence the course of AD. In the present study, we investigated how chronic T. gondii infection and resulting neuroinflammation affect plaque deposition and removal in a mouse model of AD.

resultsChronic infection with T. gondii was associated with reduced Aβ and plaque load in 5xFAD mice. Upon infection, myeloid-derived CCR2(hi) Ly6C(hi) monocytes, CCR2(+) Ly6C(int), and CCR2(+) Ly6C(low) mononuclear cells were recruited to the brain of mice. Compared to microglia, these recruited mononuclear cells showed highly increased phagocytic capacity of Aβ ex vivo. The F4/80(+) Ly6C(low) macrophages expressed high levels of Triggering Receptor Expressed on Myeloid cells 2 (TREM2), CD36, and Scavenger Receptor A1 (SCARA1), indicating phagocytic activity. Importantly, selective ablation of CCR2(+) Ly6C(hi) monocytes resulted in an increased amount of Aβ in infected mice. Elevated insulin-degrading enzyme (IDE), matrix metalloproteinase 9 (MMP9), as well as immunoproteasome subunits β1i/LMP2, β2i/MECL-1, and β5i/LMP7 mRNA levels in the infected brains indicated increased proteolytic Aβ degradation. Particularly, LMP7 was highly expressed by the recruited mononuclear cells in the brain, suggesting a novel mechanism of Aβ clearance.

conclusionsOur results indicate that chronic Toxoplasma infection ameliorates β-amyloidosis in a murine model of AD by activation of the immune system, specifically by recruitment of Ly6C(hi) monocytes and by enhancement of phagocytosis and degradation of soluble Aβ. Our findings provide evidence for a modulatory role of inflammation-induced Aβ phagocytosis and degradation by newly recruited peripheral immune cells in the pathophysiology of AD.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesAnimalsAntibodiesAntigens, CDAntigens, LyBrainCalcium-Binding ProteinsChronic DiseaseDisease Models, AnimalFemaleGlial Fibrillary Acidic ProteinHumansMacrophagesMaleMiceAif1 protein, mouseAmyloid beta-PeptidesAntibodiesAntigens, CDAntigens, LyCalcium-Binding ProteinsCcr2 protein, mouseGlial Fibrillary Acidic ProteinLy-6C antigen, mouseMicrofilament ProteinsReceptors, CCR2Alzheimer’s diseaseAβ clearanceChronic infectionLy6Chi monocytesToxoplasma gondii

Identifiers

PMID26984535
PMCPMC4793516
OpenAlexW2299895859

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.